MGMT and glioblastoma: Molecular profiling with features such as O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, observed in 35–40% of GBM cases, predicts improved responses to alkylating chemotherapy, associated with better survival outcomes [15,16,17].